Increasing demand for its services in the USA has led PharmaVentures, a leading provider of specialist consultancy and intelligence services, to appoint Jim McCarthy as its dedicated Vice President based in the United States.
Charles Macfarlane joins the Board of PharmaVentures as Non-Executive Director. PharmaVentures assists pharmaceutical and biotechnology companies worldwide in all aspects of deal making.
In response to growing industry demand, PharmaVentures, a leading provider of specialist consultancy and intelligence services, has launched a series of training programmes to provide business executives from across the world with the essential skills necessary to manage and negotiate multi-million dollar agreements.
If Pfizer and Wyeth merge to create a $60 billion company, will it be a good deal or a bad deal? Fintan Walton, PhD, CEO of PharmaVentures, says, ‘This is potentially a bad deal for both companies. By 2012, the merged company will have lost $25bn with products coming off-patent with the current pipeline only replenishing $2.5bn in that time’.
PharmaVentures, the transaction advisory and media company, announced today the launch of its new product, PharmaDeals v2, a database of deals and alliances for the pharmaceuticals sector.
PharmaVentures announced today an agreement with Growthink Research, the U.S.-based market research firm, to distribute its Venture Capital database to customers in industry and academic institutions worldwide.
PharmaTelevision®, the authoritative channel for the pharmaceutical, biotechnology and related industries, today announced that it is teaming up with the EBD Group to offer delegates at BIO-Europe a Television Interview and Media Training.
Oxford, UK, October 21 2010: In the current BioPharma economic climate; with smaller companies desperately needing the right development partners for survival and larger ones needing to support their existing businesses through making the right deals, having the best, most comprehensive, intelligence and insights are absolutely essential for success.
Increasing demand for its services in the Asia-Pacific region has led PharmaVentures, a leading provider of specialist consultancy, advisory and intelligence services, to appoint Dr Robert Daniels as its dedicated Vice President for the region. Robert will be based in Sydney, Australia.
Oxford, UK, January 19th, 2012 - PharmaVentures announced today that it was delighted to act as transaction advisor to MSD (operating in the US and Canada as Merck & Co) to secure its deal with BioCity Scotland, a new joint venture between BioCity Nottingham and Roslin BioCentre, for the former MSD research facility in Newhouse, Lanarkshire.